| PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in human and murine acute myeloid leukemia S Goswami, R Mani, J Nunes, CL Chiang, K Zapolnik, E Hu, F Frissora, ... Blood, The Journal of the American Society of Hematology 139 (9), 1340-1358, 2022 | 23* | 2022 |
| Phase I evaluation of lenvatinib and weekly paclitaxel in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal Cancer FJ Backes, L Wei, M Chen, K Hill, K Dzwigalski, M Poi, M Phelps, R Salani, ... Gynecologic Oncology 162 (3), 619-625, 2021 | 9 | 2021 |
| The neonatal fc receptor is elevated in monocyte-derived immune cells in pancreatic cancer J Thomas, MA Torok, K Agrawal, T Pfau, TT Vu, J Lyberger, H Chang, ... International journal of molecular sciences 23 (13), 7066, 2022 | 8 | 2022 |
| Murine cancer cachexia models replicate elevated catabolic pembrolizumab clearance in humans AMM Castillo, TT Vu, SG Liva, M Chen, Z Xie, J Thomas, B Remaily, ... JCSM Rapid Communications 4 (2), 232-244, 2021 | 8 | 2021 |
| Pharmacological prevention of neonatal opioid withdrawal in a pregnant guinea pig model A Safa, AR Lau, S Aten, K Schilling, KL Bales, VA Miller, J Fitzgerald, ... Frontiers in Pharmacology 11, 613328, 2021 | 5 | 2021 |
| Pharmacokinetics and tolerability of the novel non-immunosuppressive Fingolimod derivative, OSU-2S, in dogs and comparisons with data in mice and rats Z Xie, M Chen, S Goswami, R Mani, D Wang, SK Kulp, CC Coss, ... The AAPS journal 22, 1-12, 2020 | 3 | 2020 |
| Population Pharmacokinetic Analysis from First-in-Human Data for HDAC Inhibitor, REC-2282 (AR-42), in Patients with Solid Tumors and Hematologic Malignancies: A Case Study for … S Liva, M Chen, A Mortazavi, A Walker, J Wang, K Dittmar, C Hofmeister, ... European Journal of Drug Metabolism and Pharmacokinetics 46, 807-816, 2021 | 1 | 2021 |
| Decoupling FcRn and tumor contributions to elevated immune checkpoint inhibitor clearance in cancer cachexia TT Vu, K Kim, M Manna, J Thomas, BC Remaily, EJ Montgomery, T Costa, ... Pharmacological research 199, 107048, 2024 | | 2024 |
| Delineating the mechanistic pathway and therapeutic potential of Siglec-6 in Chronic Lymphocytic Leukemia JJ Nunes, A Ventura, K Zapolnik, X Mo, L Zhang, M Chen, J Byrd, ... The Journal of Immunology 208 (1_Supplement), 105.14-105.14, 2022 | | 2022 |
| 678 The neonatal Fc receptor is elevated in monocyte-derived immune cells in pancreatic cancer J Thomas, M Torok, K Agrawal, T Vu, A Castillo, M Chen, B Remaily, ... Journal for ImmunoTherapy of Cancer 9 (Suppl 2), A706-A706, 2021 | | 2021 |
| MURINE MODELS OF CANCER CACHEXIA DISPLAY ELEVATED CATABOLIC CLEARANCE OF PEMBROLIZUMAB. T Vu, A Castillo, M Chen, Z Xie, J Thomas, Y Guo, B Remaily, U Subrayan, ... CLINICAL PHARMACOLOGY & THERAPEUTICS 109, S35-S35, 2021 | | 2021 |
